<DOC>
	<DOCNO>NCT00626275</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness ADL5859 relieve pain associate rheumatoid arthritis ( RA ) compare placebo naproxen ( similar Aleve® ) . A second objective see whether effect ADL5859 differs single dose compare multiple dos .</brief_summary>
	<brief_title>Study Evaluating Analgesic Efficacy Safety ADL5859 Participants With Rheumatoid Arthritis</brief_title>
	<detailed_description>This Phase 2a study conduct 2 part . Part A randomized , single-dose , double-blind , placebo- active-controlled , 3-way crossover phase participant administer study medication clinical facility . Part B 14-day , randomize , double-blind , placebo-controlled , parallel-group , multiple-dose phase participant self-administered study medication home .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Naproxen</mesh_term>
	<mesh_term>Analgesics</mesh_term>
	<criteria>Male female participant 18 75 year age , inclusive Have document history rheumatoid arthritis ( diagnose accord American College Rheumatology criterion ) Have painful rheumatoid arthritis pain predominantly low extremity ( , hip , knee , ankle , and/or foot ) Have evoke low extremity pain intensity ( ELEPI ) score 5 high numeric pain rating scale ( NPRS ) complete Day 1 Part A dosing ( rest 45 minute walk least 10 minute treadmill ) minimum ELEPI score 4 visit Part A If receive disease modify antirheumatic drug , stable dose regimen least 30 day study entry ( 90 day study entry biologic therapy ) If biologic therapy recently discontinue , Enbrel™ Orencia™ must discontinue least 30 day study entry , Humira™ , Remicade™ , Rituxan™ must discontinue least 60 day study entry For male participant , surgically sterile agree use appropriate method contraception For female participant child bear potential , surgically sterile use insertable , injectable , transdermal , combination oral contraceptive deem highly effective US Food Drug Administration ( FDA ) completion study negative finding urine pregnancy test administration study medication ( woman postmenopausal [ menses least 2 year ] also eligible participate ) Have body weight least 45 kilogram ( kg ) Be able understand comply protocol requirement ( repeat treadmill walk diary completion via interactive voice response system ) , instruction , protocolspecified restriction . Have overall pain intensity ( OPI ) score equal 10 screen first dose study medication Part A Have pain intensity score upper body ( , back , neck , finger , wrist , elbow , and/or shoulder ) 7 numeric pain rating scale ( NPRS ) study medication administration Have history headache require prescription treatment within 6 month study entry Have significant renal disease ( indicated blood urea nitrogen serum creatinine ≥ 2 time upper limit normal ) significant hepatic disease ( indicate liver function test result ≥ 2 time upper limit normal ) Have evidence symptomatic orthostatic hypotension Have history seizure disorder , include febrile seizure Have , determine investigator sponsor 's medical monitor , history clinical manifestation significant renal , hepatic , cardiovascular , metabolic , neurologic , psychiatric , condition would affect study participation Are take cytochrome P450 ( CYP ) 3A4/5 P glycoprotein ( P gp ) transporter inhibitor Have take oral steroid within 30 day study entry intra articular steroid within 60 day study entry ( inhaled topical steroid stable oral dose ≤ 10 mg permit ) Have history presence allergy intolerance nonsteroidal antiinflammatory drug acetaminophen , history drug allergy , opinion investigator , contraindicate participation study Have history alcoholism drug addiction abuse within 5 year schedule administration study medication Have participate trial investigational medication within 30 day study drug administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Rheumatoid arthritis</keyword>
	<keyword>arthritis</keyword>
</DOC>